Full Title
Identification of Pathways to Mitigate Immune-Related Adverse Events with Cancer (BRANY)Purpose
Treatment for cancer can cause unwanted side effects affecting the skin that may be associated with itching or pain. These side effects may have a direct link to the immune system’s response to cancer.
The purpose of this study is to see if people receiving checkpoint inhibitor immunotherapy (such as pembrolizumab, nivolumab, or similar immunotherapy drugs) and who experience skin side effects may have unique immunologic features that are connected with these responses. It may be possible that these features will help guide the search for cures for these side effects.
This study will involve two groups: one for people receiving immunotherapy and who developed a skin side effect, and the other group for people receiving immunotherapy who did not experience skin side effects. Researchers will compare the results of blood, urine, skin sample, and other tests between the two groups. It is hoped that the results of this study will help doctors better understand how to treat skin reactions in patients receiving cancer immunotherapy.
Who Can Join
This study is for patients age 18 and older at Memorial Sloan Kettering Cancer Center who are receiving checkpoint inhibitor immunotherapy for a solid tumor such as melanoma or a genitourinary, gynecologic, lung, or digestive cancer.
Contact
For more information and to ask about eligibility for this study, please contact the office of Dr. Alina Markova at 646-608-2342.